Trials / Terminated
TerminatedNCT05083078
A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis
A Phase 1 Study to Assess the Relative PK and Tissue Distribution of Guselkumab and Risankizumab in Healthy Participants and Patients With Psoriatic Arthritis
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the tissue distribution of guselkumab and risankizumab in healthy participants (Part 1) and psoriatic arthritis (PsA) participants (Part 2 and Part 3).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Guselkumab | Guselkumab will be administered subcutaneously. |
| DRUG | Risankizumab | Risankizumab will be administered subcutaneously. |
Timeline
- Start date
- 2021-11-04
- Primary completion
- 2022-07-01
- Completion
- 2022-07-01
- First posted
- 2021-10-19
- Last updated
- 2022-07-26
Locations
1 site across 1 country: Austria
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05083078. Inclusion in this directory is not an endorsement.